# Prediction

I predict **denial**, with a **42% probability of any grant**. If the Court grants, the likeliest form is plenary certiorari rather than a GVR. Denial remains individually more likely because the Solicitor General has not yet filed the invited brief and even CVSG petitions are denied more often than granted.

## Questions and governing standard

The petition presents two questions arising from Oregon HB 4005. First, it asks whether a government reporting mandate compelling product-specific narrative explanations is commercial speech subject to intermediate scrutiny and whether correcting information asymmetries is enough to satisfy that scrutiny. Second, it asks whether participation in a highly regulated industry categorically defeats reasonable investment-backed expectations in trade secrets under the Takings Clause.

At the certiorari stage, the important considerations are the Rule 10-type signals: a genuine conflict among courts of appeals, an important recurring federal question, a clean vehicle, and a need for Supreme Court intervention rather than mere error correction. On the merits described in the petition, compelled noncommercial speech generally receives strict scrutiny; commercial-speech restrictions receive Central Hudson intermediate scrutiny. A regulatory-takings claim ordinarily applies the Penn Central factors, while Ruckelshaus v. Monsanto recognizes trade secrets as property and makes the regulatory bargain relevant to investment-backed expectations.

## Record signals

The provisioned July 16 snapshot shows a paid petition from the Ninth Circuit, a published divided panel decision, denial of rehearing, a response requested after an initial waiver, full briefing, and—most importantly—a June 22 invitation for the Solicitor General's views. A CVSG is a strong indication that at least some Justices regard the questions as serious and potentially certworthy. The petition also offers unusually favorable vehicle facts: a facial challenge resolved on cross-motions for summary judgment, no identified material factual dispute, two issues expressly decided below, and a First Amendment dissent.

The petition alleges concrete conflicts. On compelled disclosure, it contrasts the Ninth Circuit's product-specific reporting rule and information-asymmetry rationale with Second and D.C. Circuit decisions requiring more than consumer curiosity or a circular desire for information. On takings, it contrasts the Ninth Circuit's treatment of a highly regulated market with the First Circuit's en banc decision in Philip Morris and Federal Circuit decisions treating regulation as one consideration rather than a categorical bar. The questions also reach beyond one pharmaceutical-pricing law to state transparency mandates in other regulated industries. Those features materially raise the case above the ordinary paid petition.

There are important reasons not to cross 50%. The claims of conflict come from the petition, and the provisioned document set does not include the filed brief in opposition or the Solicitor General's eventual views. The First Amendment issue may be viewed as an application of commercial-speech doctrine rather than a square split, and the Takings Clause question may turn on the particular statutory and regulatory expectations surrounding pharmaceutical disclosures. The Court may also wait for further lower-court development. A CVSG signals interest, not agreement with the petitioner.

## Calibration

The committed statpack estimates a 5.36% grant rate for paid 2025 Term petitions and a 3.0% grant rate for modern cert petitions from the Ninth Circuit. Those broad rates are much less informative here than the selected-case signal: the statpack's resolved CVSG bucket has a 27.1% grant rate. I move above that CVSG anchor because this petition combines a divided published decision, multiple facial constitutional questions, asserted circuit conflicts, a clean summary-judgment posture, experienced Supreme Court counsel, and broad regulatory consequences. I stop at 42% because the United States has not yet taken a position and denial remains the historical modal outcome even among CVSG cases.

The **0.78 big-case score** reflects the potential significance if decided: the case could affect pharmaceutical-price transparency, trade-secret protection, compelled business speech, and disclosure regimes across regulated industries. That stakes assessment is separate from the grant probability.

## Inputs and retrieval limits

I relied on the event definition, the July 16 snapshot, `documents.json`, the provisioned questions presented, and the 44-page petition. Although the snapshot records a May 28 brief in opposition, its text was not included in the provisioned document set, so I did not infer its arguments. CourtListener searches supplied only pre-snapshot legal context, including the Ninth Circuit opinion's metadata, and revealed no Supreme Court disposition. Two corpus-prior commands failed before returning rows because the remote host could not be resolved; the probability therefore uses the committed statpack rather than retrieved comparable cases.
